Antifungal F2G Raises $60m, Sees Harmonized Route To Market

UK-based antifungal company F2G has raised $60m as it prepares a pivotal trial of its lead drug candidate for the treatment of invasive fungal infections. With both oral and IV formulations of its lead candidate and a harmonized regulatory pathway agreed with the US FDA and EMA, CEO Ian Nicholson believes a 2019 filing is achievable.